Issue 1, 2019

Benzoflavone derivatives as potent antihyperuricemic agents

Abstract

Two series of benzoflavone derivatives were rationally designed, synthesized and evaluated for their xanthine oxidase (XO) inhibitory potential. Among both series, eight compounds (NF-2, NF-4, NF-9, NF-12, NF-16, NF-25, NF-28, and NF-32) were found to exert significant XO inhibition with IC50 values lower than 10 μM. Enzyme kinetic studies revealed that the most potent benzoflavone derivatives (NF-4 and NF-28) are mixed type inhibitors of the XO enzyme. Molecular modeling studies were also performed to investigate the binding interactions of these molecules (NF-4 and NF-28) with the amino acid residues present in the active site of the enzyme. Docking results confirmed that their favorable binding conformations in the active site of XO can completely block the catalytic activity of the enzyme. Benzoflavone derivatives exhibiting potent XO enzyme inhibition also showed promising results in a hyperuricemic mice model when tested in vivo.

Graphical abstract: Benzoflavone derivatives as potent antihyperuricemic agents

Associated articles

Supplementary files

Article information

Article type
Research Article
Submitted
10 Oct 2018
Accepted
05 Dec 2018
First published
06 Dec 2018

Med. Chem. Commun., 2019,10, 128-147

Benzoflavone derivatives as potent antihyperuricemic agents

J. V. Singh, G. Mal, G. Kaur, M. K. Gupta, A. Singh, K. Nepali, H. Singh, S. Sharma and P. M. S. Bedi, Med. Chem. Commun., 2019, 10, 128 DOI: 10.1039/C8MD00512E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements